Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study

BACKGROUND: Clinical trials demonstrated that women treated for breast cancer with anthracycline or trastuzumab are at increased risk for heart failure and/or cardiomyopathy (HF/CM), but the generalizability of these findings is unknown. We estimated real-world adjuvant anthracycline and trastuzumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowles, Erin J. Aiello, Wellman, Robert, Feigelson, Heather Spencer, Onitilo, Adedayo A., Freedman, Andrew N., Delate, Thomas, Allen, Larry A., Nekhlyudov, Larissa, Goddard, Katrina A. B., Davis, Robert L., Habel, Laurel A., Yood, Marianne Ulcickas, Mccarty, Catherine, Magid, David J., Wagner, Edward H., Pharmacovigilance Study Team
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433392/
https://www.ncbi.nlm.nih.gov/pubmed/22949432
http://dx.doi.org/10.1093/jnci/djs317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433392/
https://www.ncbi.nlm.nih.gov/pubmed/22949432
http://dx.doi.org/10.1093/jnci/djs317

Ejemplares similares